Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, +617

The Lancet Oncology

5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical Trials +8

Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer

Joyce O’Shaughnessy, Lee Schwartzberg, Michael Danso, +14

Journal of Clinical Oncology

Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer

Takayuki Iwamoto, Giampaolo Bianchini, Daniel J. Booser, +14

JNCI Journal of the National Cancer Institute

Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation

Gregory A. Yanik, Beth A. Hellerstedt, Joseph R. Custer, +5

Biology of Blood and Marrow Transplantation

Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers

Libero Santarpia, Yuan Qi, Katherine Stemke‐Hale, +16

Breast Cancer Research and Treatment

Breast OncologyOncologyEngineeringSomatic VariantTumor Heterogeneity +12

Gemcitabine, Cisplatin, and Sunitinib for Metastatic Urothelial Carcinoma and as Preoperative Therapy for Muscle-Invasive Bladder Cancer

Matthew D. Galsky, Noah M. Hahn, Thomas Powles, +14

Clinical Genitourinary Cancer

UrologyMetastatic Urothelial CarcinomaGenitourinary CancerMedicinePharmacology +4

The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy.

M T Lotze, Beth A. Hellerstedt, L. A. Stolinski, +9

PubMed

Administration of Cisplatin-Based Chemotherapy for Advanced Urothelial Carcinoma in the Community

Guru Sonpavde, Deidre Watson, Marcia Tourtellott, +5

Clinical Genitourinary Cancer

UrologyOncologyCisplatin-based ChemotherapyGenitourinary CancerCancer Management +6

A phase 1 study of MM-111, a bispecific HER2/HER3 antibody fusion protein, combined with multiple treatment regimens in patients with advanced HER2-positive solid tumors.

Donald Richards, Fadi S. Braiteh, Agustin A. García, +13

Journal of Clinical Oncology

Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen‐independent prostate carcinoma

Beth A. Hellerstedt, Kenneth J. Pienta, Bruce G. Redman, +5

Cancer